The serum concentration of Olanzapine can be increased when it is combined with Panobinostat. The therapeutic efficacy of Piribedil can be decreased when used in combination with Olanzapine. Olanzapine may increase the QTc-prolonging activities of Promazine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Remoxipride. The risk or severity of adverse effects can be increased when Olanzapine is combined with Piritramide. Olanzapine may increase the QTc-prolonging activities of Telithromycin. The metabolism of Olanzapine can be decreased when combined with Zucapsaicin. The risk or severity of adverse effects can be increased when Olanzapine is combined with Methylphenobarbital. The risk or severity of adverse effects can be increased when Clorazepate is combined with Olanzapine. The therapeutic efficacy of Apomorphine can be decreased when used in combination with Olanzapine. The serum concentration of Olanzapine can be decreased when it is combined with Teriflunomide. The risk or severity of adverse effects can be increased when Olanzapine is combined with Levobupivacaine. The therapeutic efficacy of Allicin can be decreased when used in combination with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Gamma Hydroxybutyric Acid. Olanzapine may increase the QTc-prolonging activities of Escitalopram. The serum concentration of Olanzapine can be increased when it is combined with Vemurafenib. The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Olanzapine. The risk or severity of adverse effects can be increased when Camazepam is combined with Olanzapine. Olanzapine can cause a decrease in the absorption of Pazopanib resulting in a reduced serum concentration and potentially a decrease in efficacy. The risk or severity of adverse effects can be increased when Olanzapine is combined with Raclopride. The risk or severity of adverse effects can be increased when Olanzapine is combined with Tasimelteon. The risk or severity of adverse effects can be increased when Olanzapine is combined with Fospropofol. The risk or severity of adverse effects can be increased when Olanzapine is combined with Perospirone. The risk or severity of adverse effects can be increased when Olanzapine is combined with Loxapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Ethchlorvynol. Hydracarbazine may increase the serotonergic activities of Olanzapine. Olanzapine may increase the QTc-prolonging activities of Dolasetron. The risk or severity of adverse effects can be increased when Olanzapine is combined with Dihydrocodeine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Zopiclone. Olanzapine may increase the QTc-prolonging activities of Pimozide. The risk or severity of adverse effects can be increased when Olanzapine is combined with Ritanserin. Olanzapine may increase the QTc-prolonging activities of Dofetilide. The risk or severity of adverse effects can be increased when Olanzapine is combined with Ethylmorphine. The serum concentration of Olanzapine can be decreased when it is combined with Cyproterone acetate. The therapeutic efficacy of Cysteamine can be decreased when used in combination with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Amitriptyline. The risk or severity of adverse effects can be increased when Olanzapine is combined with Isoflurane. The risk or severity of adverse effects can be increased when Olanzapine is combined with Levomethadyl Acetate. The risk or severity of adverse effects can be increased when Vilazodone is combined with Olanzapine. The risk or severity of adverse effects can be increased when Metergoline is combined with Olanzapine. The risk or severity of adverse effects can be increased when Hydromorphone is combined with Olanzapine. Minocycline may increase the central nervous system depressant (CNS depressant) activities of Olanzapine. The serum concentration of Erlotinib can be decreased when it is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Amperozide. Dapoxetine may increase the serotonergic activities of Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Ramelteon. The risk or severity of adverse effects can be increased when Olanzapine is combined with Dihydromorphine. The risk or severity of adverse effects can be increased when Mesoridazine is combined with Olanzapine. Olanzapine may increase the QTc-prolonging activities of Quetiapine. Olanzapine may increase the QTc-prolonging activities of Propafenone. The risk or severity of adverse effects can be increased when Olanzapine is combined with Phenytoin. The risk or severity of adverse effects can be increased when Olanzapine is combined with Gepirone. Toloxatone may increase the serotonergic activities of Olanzapine. Olanzapine may increase the QTc-prolonging activities of Clarithromycin. The risk or severity of adverse effects can be increased when Olanzapine is combined with Thiopental. The metabolism of Olanzapine can be decreased when combined with Paroxetine. Olanzapine may decrease the stimulatory activities of Midomafetamine. The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Olanzapine. Iproclozide may increase the serotonergic activities of Olanzapine. The therapeutic efficacy of Linagliptin can be decreased when used in combination with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Norflurane. The risk or severity of adverse effects can be increased when Olanzapine is combined with Efavirenz. The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Triprolidine. The risk or severity of adverse effects can be increased when Promethazine is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Protriptyline. The metabolism of Olanzapine can be decreased when combined with Atomoxetine. The serum concentration of Saquinavir can be increased when it is combined with Olanzapine. Olanzapine may increase the QTc-prolonging activities of Lenvatinib. Pheniprazine may increase the serotonergic activities of Olanzapine. Alaproclate may increase the serotonergic activities of Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Zaleplon. Olanzapine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Phenoxypropazine may increase the serotonergic activities of Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Desflurane. The risk or severity of adverse effects can be increased when Olanzapine is combined with Enflurane. The risk or severity of adverse effects can be increased when Olanzapine is combined with DPDPE. The risk or severity of adverse effects can be increased when Phenelzine is combined with Olanzapine. The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Olanzapine. The serum concentration of Atazanavir can be decreased when it is combined with Olanzapine. The risk or severity of adverse effects can be increased when Almotriptan is combined with Olanzapine. The risk or severity of adverse effects can be increased when Flurazepam is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Opium. The serum concentration of Posaconazole can be decreased when it is combined with Olanzapine. Olanzapine may increase the QTc-prolonging activities of Flecainide. The risk or severity of adverse effects can be increased when Olanzapine is combined with Ziconotide. Olanzapine may increase the QTc-prolonging activities of Haloperidol. Octamoxin may increase the serotonergic activities of Olanzapine. The risk or severity of adverse effects can be increased when Eletriptan is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Oxethazaine. Olanzapine may decrease the stimulatory activities of Benzphetamine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Amoxapine. The metabolism of Olanzapine can be decreased when combined with Simeprevir. The risk or severity of adverse effects can be increased when Fluphenazine is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Ethosuximide. The metabolism of Olanzapine can be decreased when combined with Cimetidine. Olanzapine may increase the QTc-prolonging activities of Ziprasidone. Mifepristone may increase the QTc-prolonging activities of Olanzapine. The therapeutic efficacy of Tolazamide can be decreased when used in combination with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Guanfacine. Olanzapine can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects. The risk or severity of adverse effects can be increased when Olanzapine is combined with Cyclobenzaprine. Olanzapine may decrease the stimulatory activities of Phentermine. Olanzapine may increase the QTc-prolonging activities of Citalopram. Olanzapine may increase the QTc-prolonging activities of Flupentixol. The serum concentration of Cerivastatin can be increased when it is combined with Olanzapine. The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Olanzapine. The serum concentration of Olanzapine can be increased when it is combined with Cobicistat. Olanzapine may increase the QTc-prolonging activities of Goserelin. The risk or severity of adverse effects can be increased when Olanzapine is combined with Alfaxalone. The risk or severity of adverse effects can be increased when BL-1020 is combined with Olanzapine. Olanzapine may decrease the stimulatory activities of MMDA. The metabolism of Olanzapine can be decreased when combined with Celecoxib. The risk or severity of adverse effects can be increased when Olanzapine is combined with Loprazolam. The serum concentration of Rilpivirine can be increased when it is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Aceprometazine. Olanzapine may increase the QTc-prolonging activities of Asenapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Tiagabine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Meprobamate. Olanzapine may increase the central nervous system depressant (CNS depressant) activities of Ethanol. Olanzapine may increase the QTc-prolonging activities of Ibutilide. The risk or severity of adverse effects can be increased when Moclobemide is combined with Olanzapine. The therapeutic efficacy of Glimepiride can be decreased when used in combination with Olanzapine. The risk or severity of adverse effects can be increased when Perazine is combined with Olanzapine. Indalpine may increase the serotonergic activities of Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Cyproheptadine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Ecopipam. The risk or severity of adverse effects can be increased when Olanzapine is combined with Chlorphenamine. The metabolism of Olanzapine can be decreased when combined with Betaxolol. The metabolism of Olanzapine can be decreased when combined with Lidocaine.